Travere Therapeutics (TVTX) Expected to Announce Quarterly Earnings on Thursday

Travere Therapeutics (NASDAQ:TVTX) is anticipated to issue its Q4 2025 results after the market closes on Thursday, February 19th. Analysts expect the company to announce earnings of ($0.05) per share and revenue of $147.6840 million for the quarter. Parties may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, February 19, 2026 at 4:30 PM ET.

Travere Therapeutics Stock Performance

Travere Therapeutics stock opened at $28.75 on Wednesday. Travere Therapeutics has a 12-month low of $12.91 and a 12-month high of $42.13. The company has a debt-to-equity ratio of 4.23, a current ratio of 2.75 and a quick ratio of 2.71. The company has a market capitalization of $2.57 billion, a price-to-earnings ratio of -27.12, a price-to-earnings-growth ratio of 0.76 and a beta of 0.83. The firm’s fifty day moving average price is $33.01 and its 200 day moving average price is $28.75.

Insider Activity

In other news, CFO Christopher R. Cline sold 20,000 shares of Travere Therapeutics stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $35.01, for a total value of $700,200.00. Following the completion of the transaction, the chief financial officer directly owned 92,083 shares of the company’s stock, valued at approximately $3,223,825.83. The trade was a 17.84% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Elizabeth E. Reed sold 10,000 shares of the business’s stock in a transaction dated Tuesday, January 20th. The shares were sold at an average price of $27.34, for a total transaction of $273,400.00. Following the sale, the insider directly owned 90,270 shares of the company’s stock, valued at approximately $2,467,981.80. This represents a 9.97% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 331,925 shares of company stock valued at $11,318,755 over the last three months. 4.06% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Travere Therapeutics

Several institutional investors have recently made changes to their positions in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Travere Therapeutics by 13.7% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 56,777 shares of the company’s stock worth $1,029,000 after purchasing an additional 6,831 shares during the last quarter. Norges Bank bought a new stake in Travere Therapeutics in the second quarter valued at $1,051,000. First Trust Advisors LP bought a new stake in Travere Therapeutics in the second quarter valued at $3,538,000. Cresset Asset Management LLC boosted its holdings in shares of Travere Therapeutics by 26.5% during the second quarter. Cresset Asset Management LLC now owns 28,875 shares of the company’s stock valued at $427,000 after acquiring an additional 6,047 shares during the period. Finally, Qube Research & Technologies Ltd grew its position in shares of Travere Therapeutics by 106.2% during the second quarter. Qube Research & Technologies Ltd now owns 604,128 shares of the company’s stock worth $8,941,000 after acquiring an additional 311,137 shares during the last quarter.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the company. HC Wainwright reissued a “buy” rating and issued a $47.00 price target on shares of Travere Therapeutics in a report on Friday, November 28th. Piper Sandler increased their target price on Travere Therapeutics from $35.00 to $38.00 and gave the company a “neutral” rating in a research note on Friday, February 6th. TD Cowen reissued a “buy” rating on shares of Travere Therapeutics in a research report on Friday, October 31st. Zacks Research cut shares of Travere Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, November 12th. Finally, Wall Street Zen upgraded shares of Travere Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Saturday, December 13th. Eleven research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $38.62.

About Travere Therapeutics

Travere Therapeutics, Inc (NASDAQ: TVTX) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company’s mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company’s lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.